Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study
International Journal of Clinical Oncology · 2025
DOI: 10.1007/s10147-025-02708-2 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Clinical Oncology, 2025. Verfasst von Mototsugu Oya und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Keio University School of Medicine, Tokyo, Japan. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Antibodies, Monoclonal, Humanized, Kidney Neoplasms, Antineoplastic Combined Chemotherapy Protocols. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MSD K.K..
Themen: Patientensicherheit
Abstract (Originalsprache)
Background
Post-marketing surveillance focusing on hepatic function disorder was requested owing to its higher incidence in the pembrolizumab plus axitinib group than in the sunitinib group in KEYNOTE-426. We aimed to evaluate the prevalence and risk factors of adverse events (AEs) of hepatic function disorder in patients with unresectable/metastatic renal cell carcinoma (RCC) treated with pembrolizumab plus axitinib in real-world clinical practice in Japan.
Methods
Patients were observed for 9 months after starting treatment with pembrolizumab plus axitinib.
Results
In total, 193 patients were included in the safety analysis set (median age, 70 years). Most patients did not have a history of hepatic function disorder before starting treatment (96.4%, 186/193). The median treatment period was 27.1 weeks. At the 9-month data cut-off, 62.2% (120/193) of patients discontinued treatment, the most common reason being any AE in 31.1% (60/193). The incidence of AEs of hepatic function disorder was 30.1% (58/193) for any grade and 15.0% (29/193) for grade ≥ 3. Most AEs of hepatic function disorder occurred within 3 months from starting treatment. AEs of hepatic function disorder were the reason for discontinuation of pembrolizumab in 9.3% (18/193) of patients; axitinib, 7.3% (14/193); and both pembrolizumab and axitinib, 5.2% (10/193). No background factors were identified as being associated with the occurrence of AEs of hepatic function disorder.
Conclusion
There were no new safety signals for AEs of hepatic function disorder, and the incidence was consistent with that reported in KEYNOTE-426, in Japanese patients with radically unresectable/metastatic RCC treated with pembrolizumab plus axitinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Keio University School of Medicine, Tokyo, Japan.
- Oncology Medical Affairs, MSD K.K., 1‑13‑12 Kudan‑kita, Chiyoda‑ku, Tokyo, 102‑8667, Japan.
- Oncology Medical Affairs, MSD K.K., 1‑13‑12 Kudan‑kita, Chiyoda‑ku, Tokyo, 102‑8667, Japan. takuto.tokudome@merck.com.
- Japan Pharmacovigilance, MSD K.K., Tokyo, Japan.
Förderung
- MSD K.K.
Zitieren
APA
Oya, M., Yasuoka, S., Tokudome, T., Minegishi, T., Hamada, M., Ozaki, M., Maekawa, S., & Ito, Y. (2025). Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study. International Journal of Clinical Oncology. https://doi.org/10.1007/s10147-025-02708-2
Vancouver
Oya M, Yasuoka S, Tokudome T, Minegishi T, Hamada M, Ozaki M, et al. Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study. International Journal of Clinical Oncology. 2025. doi:10.1007/s10147-025-02708-2
BibTeX
@article{Oya2025,
author = {Oya, Mototsugu and Yasuoka, Shotaro and Tokudome, Takuto and Minegishi, Toshihiko and Hamada, Masahiro and Ozaki, Masahiko and Maekawa, Shinichiroh and Ito, Yuichiro},
title = {Adverse events of hepatic function disorder in Japanese patients with radically unresectable or metastatic renal cell carcinoma treated with pembrolizumab plus axitinib: a post-marketing surveillance study},
journal = {International Journal of Clinical Oncology},
year = {2025},
doi = {10.1007/s10147-025-02708-2}
}
EUVIMED